Browsing by author "Kaiser, Martin"
Now showing items 21-40 of 86
-
Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study.
Satchwell, L; Wedlake, L; Greenlay, E; Li, X; Messiou, C; et al. (BMJ PUBLISHING GROUP, 2022-10-05)INTRODUCTION: Whole-body MRI (WB-MRI) is recommended by the National Institute of Clinical Excellence as the first-line imaging tool for diagnosis of multiple myeloma. Reporting WB-MRI scans requires expertise to interpret ... -
Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma.
Bygrave, C; Pawlyn, C; Davies, F; Craig, Z; Cairns, D; et al. (WILEY, 2020-06-10)Predicting patient outcome in multiple myeloma remains challenging despite the availability of standard prognostic biomarkers. We investigated outcome for patients relapsing early from intensive therapy on NCRI Myeloma XI. ... -
Exploiting gene dependency to inform drug development for multiple myeloma.
Went, M; Hoang, PH; Law, PJ; Kaiser, MF; Houlston, RS (NATURE PORTFOLIO, 2022-07-26)Despite recent advances in therapy, multiple myeloma essentially remains an incurable malignancy. Targeting tumour-specific essential genes, which constitute a druggable dependency, potentially offers a strategy for ... -
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
Luo, MM; Usmani, SZ; Mateos, M-V; Nahi, H; Chari, A; et al. (WILEY, 2020-11-03)We report the population pharmacokinetic (PK) and exposure-response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) ... -
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Usmani, SZ; Nahi, H; Legiec, W; Grosicki, S; Vorobyev, V; et al. (FERRATA STORTI FOUNDATION, 2022-10-01)In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA IV) for relapsed or refractory multiple myeloma ... -
Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.
Coulson, AB; Royle, K-L; Pawlyn, C; Cairns, DA; Hockaday, A; et al. (BMJ PUBLISHING GROUP, 2022-06-02)INTRODUCTION: Multiple myeloma is a bone marrow cancer, which predominantly affects older people. The incidence is increasing in an ageing population.Over the last 10 years, patient outcomes have improved. However, this ... -
Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
Ajore, R; Niroula, A; Pertesi, M; Cafaro, C; Thodberg, M; et al. (NATURE PORTFOLIO, 2022-01-10)Thousands of non-coding variants have been associated with increased risk of human diseases, yet the causal variants and their mechanisms-of-action remain obscure. In an integrative study combining massively parallel ... -
Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.
Went, M; Sud, A; Speedy, H; Sunter, NJ; Försti, A; et al. (NATURE PUBLISHING GROUP, 2018-12-21)The clustering of different types of B-cell malignancies in families raises the possibility of shared aetiology. To examine this, we performed cross-trait linkage disequilibrium (LD)-score regression of multiple myeloma ... -
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li, N; Johnson, DC; Weinhold, N; Kimber, S; Dobbins, SE; et al. (CELL PRESS, 2017-09-12)Multiple myeloma (MM) is a malignancy of plasma cells. Genome-wide association studies have shown that variation at 5q15 influences MM risk. Here, we have sought to decipher the causal variant at 5q15 and the mechanism by ... -
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
Law, PJ; Sud, A; Mitchell, JS; Henrion, M; Orlando, G; et al. (NATURE PORTFOLIO, 2017-01-23)B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been identified, an agnostic, ... -
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.
Mitchell, JS; Li, N; Weinhold, N; Försti, A; Ali, M; et al. (NATURE PUBLISHING GROUP, 2016-07-01)Multiple myeloma (MM) is a plasma cell malignancy with a significant heritable basis. Genome-wide association studies have transformed our understanding of MM predisposition, but individual studies have had limited power ... -
Germline variants at SOHLH2 influence multiple myeloma risk.
Duran-Lozano, L; Thorleifsson, G; Lopez de Lapuente Portilla, A; Niroula, A; Went, M; et al. (SPRINGERNATURE, 2021-04-19)Multiple myeloma (MM) is caused by the uncontrolled, clonal expansion of plasma cells. While there is epidemiological evidence for inherited susceptibility, the molecular basis remains incompletely understood. We report a ... -
Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS).
Messiou, C; Hillengass, J; Delorme, S; Lecouvet, FE; Moulopoulos, LA; et al. (RADIOLOGICAL SOC NORTH AMERICA, 2019-04-01)Acknowledging the increasingly important role of whole-body MRI for directing patient care in myeloma, a multidisciplinary, international, and expert panel of radiologists, medical physicists, and hematologists with specific ... -
High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro Research.
Menezes, K; Atanesyan, L; Sherborne, AL; Steenkamer, M; Clemens, I; et al. (ELSEVIER SCIENCE INC, 2020-09-01)Tumor cell lines are widely used for cancer research, but challenges regarding quality control of cell line identity, cross contamination, and tumor somatic molecular stability remain, demanding novel approaches beyond ... -
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; et al. (2018-09-13)Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ... -
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.
Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; et al. (NATURE PUBLISHING GROUP, 2018-09-13)Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ... -
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
Keaveney, S; Dragan, A; Rata, M; Blackledge, M; Scurr, E; et al. (SPRINGER WIEN, 2023-10-15)BACKGROUND: The Myeloma Response Assessment and Diagnosis System (MY-RADS) guidelines establish a standardised acquisition and analysis pipeline for whole-body MRI (WB-MRI) in patients with myeloma. This is the first study ... -
Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
Faustini, SE; Hall, A; Brown, S; Roberts, S; Hill, H; et al. (WILEY, 2023-06-01)Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome ... -
Impact of mitochondrial DNA mutations in multiple myeloma.
Hoang, PH; Cornish, AJ; Chubb, D; Jackson, G; Kaiser, M; et al. (NATURE PUBLISHING GROUP, 2020-05-01) -
Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.
Panopoulou, A; Easdale, S; Ethell, M; Nicholson, E; Potter, M; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2023-02-01)Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We ...